Kejin Bio Completes Nearly RMB 100 Million Financing to Tackle 'Bottleneck' Challenges in Cell Culture Materials

According to VCBeat, Shanghai Kejin Biotechnology Co., Ltd., a leading domestic enterprise in high-end laboratory consumables and new materials,(hereinafter referred to as "Kejin Bio")Announces Completion of Nearly RMB 100 Million in New Round of Financing, Led by Industrial Capital Management Co., Ltd., with Participation from ADDOR and Yaojin Capital. The proceeds will be used to sustain R&D investment in "chokepoint" areas such as high-end laboratory consumables and new materials for cell culture, expand the production base for high-end laboratory consumables, and promote related products.

Kejin Biologics, headquartered in Zhangjiang, Shanghai, is a high-tech enterprise dedicated to the research and development of high-end laboratory consumables and foundational innovative materials that are currently subject to import monopolies and represent critical technological bottlenecks.The company’s current main products include high-end laboratory consumables and membrane products for liquid handling, molecular biology, and cell storage and culture, which are primarily applied in biopharmaceutical-related fields such as basic scientific research, in vitro diagnostics, vaccines, cell therapy, antibody drugs, and gene therapy.The company possesses full-industry-chain capabilities spanning raw material R&D, polymer modification and coating, high-quality production of premium products, and sales. Its products have been integrated into the procurement systems of numerous top-tier pharmaceutical and CXO companies, establishing it as a leading enterprise in China’s high-end laboratory consumables sector.

Kejin Biology Successfully Breaks the Monopoly of Developed Countries on Polymer Material Formulations and Modified Coating Technologies in the Fields of Molecular and Cell Biology.In the field of high-end laboratory consumables for molecular and cell biology, polymer material formulations and subsequent modification and processing techniques constitute core technological barriers. Currently, the domestic market for high-end products is predominantly monopolized by foreign life science giants such as Corning, Thermo Fisher Scientific, Sartorius, and Eppendorf. The high prices and long lead times associated with these products have become a key bottleneck constraining the rapid development of China’s biopharmaceutical industry.

Since its inception, Kejin Biology has been dedicated to mastering foundational technologies, accumulating expertise for sustained growth, and strictly controlling manufacturing processes. The company has successfully developed a range of high-end products, including next-generation automated liquid handling consumables, bioprocessing bag films, and premium cell culture consumables. As one of the few enterprises in China capable of both successful R&D and mass production in the fields of scientific research, biopharmaceuticals, and in vitro diagnostics (IVD), Kejin Biology has commenced external sales and promotional activities. Its robust competitive barriers are built upon polymer raw material modification, independently developed production process formulations, fully proprietary intellectual property rights for manufacturing processes, and scientifically designed automated production lines.

The company has long prioritized the optimization of manufacturing processes and stringent quality control throughout production. Its products have gained recognition and preference from numerous foreign-funded pharmaceutical companies and publicly listed enterprises in the pharmaceutical industry, successfully entering the procurement systems of high-quality clients. With the rapid development and maturation of China’s biopharmaceutical industry, the market scale for upstream consumables in biopharmaceuticals and in vitro diagnostics will continue to expand. Upholding a consistent craftsman spirit over many years, Kejin Bio will always fulfill its mission as a premium domestic Chinese brand, contributing to the robust growth of China’s biopharmaceutical industry with the highest-quality products.

Regarding the success of this financing round,Mr. Zhu Yiming, Chairman of Kejin BiologyStatement: For a long time, Kejin Bio has been committed to providing high-quality laboratory consumables for the domestic life sciences sector. We will spare no effort to help Chinese enterprises break free from dependence on overseas companies in the fields of molecular biology and cell biology. We sincerely appreciate the recognition from leading healthcare investors, Industrial Capital Management Co., Ltd. (Xingzheng Capital) and ADDOR Capital, as well as the continued support from our strategic shareholder, Sinopharm Holding Yaojin Capital. We will continue to uphold our corporate philosophy of “Surpassing Ourselves, Pursuing Excellence,” promote national brands, and provide the highest quality products to our partners in China’s life sciences field.

Xiang Jun, Vice President of Industrial Capital“It stated: ‘The rise of China’s life sciences industry has driven the rapid development of the upstream laboratory consumables sector. As a leading enterprise in the life sciences laboratory consumables industry, Kejin Biology has built a portfolio of high-end laboratory consumables products based on its independently developed core technologies, providing strong support and assurance for the innovative development of China’s life sciences industry and the security of laboratory consumables supply. We believe that under the leadership of the company’s management team, Kejin Biology will accelerate its development in high-end products, core technologies, and domestic and international markets, continuing to lead the industry. Industrial Capital Management Co., Ltd. will also continue to leverage its professional advantages to support the company’s growth.’”

ADDOR Partner Huang Liqun“It is stated that, driven by the rapid overall development of China’s pharmaceutical industry and the continuous increase in the number and investment of clinical trials, market demand for biological laboratory consumables will continue to expand, with domestic brands gradually achieving import substitution. As a leading Chinese brand of laboratory consumables, Kejin Biology has made innovative breakthroughs at the raw material stage of biological laboratory consumables, holding the promise of localizing key materials currently subject to supply bottlenecks in China. ADDOR Capital will continue to support Kejin Biology in scaling up and strengthening its market position.”

Mr. Li Ke, General Manager of Yaojin Capital“It is gratifying to see Kejinhui Biology complete this round of financing. As a strategic shareholder, Yaojin Capital continues to strengthen its support for Kejinhui Biology, facilitating its technological breakthroughs in critical areas where China faces bottlenecks. The quality of high-end laboratory consumables is closely linked to R&D outcomes. There remains a significant technological gap between domestic enterprises and overseas giants in this field. We hope that Kejinhui Biology, as a leading brand specializing in ‘small, precise, distinctive, and specialized’ products, will sustain its R&D investment and expand its product portfolio, thereby providing high-quality, domestically produced products to downstream customers.”